Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Danish Cancer Society
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02895724CT.gov Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphedema
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxygen (this asset) | Danish Cancer Society | P2 | CCC · 53 |
| Pycnogenol | National Center for Complementary and Integrative Health (NCCIH) | P2 | B |
| Tacrolimus | Odense University Hospital | P2/3 | B |
| Lymfactin® | Herantis Pharma Plc. | P2 | B |
| Pentoxifylline | M.D. Anderson Cancer Center | P2 | B |
| Sodium Selenite | University Health Network, Toronto | P2 | B |
| Indocyanine Green | City of Hope Medical Center | P2 | CCC |
| Deupirfenidone | PureTech | P2 | CCC |
| Tocopherol | M.D. Anderson Cancer Center | P2 | CCC |
+9 more in the Lymphedema cohort
Other indications for Oxygen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anxiety Disorder | — | P4 | BB · 66 |
| Benign Prostatic Hyperplasia | — | P4 | BB · 66 |
| Prostate Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxygen in Lymphedema. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxygen-lymphedema
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →